ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2522

Frequency and Early Prediction of Hydroxychloroquine Induced Retinopathy in SLE

Jessica Li1, Daniel Goldman 2 and Michelle Petri 1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: hydroxychloroquine and retinopathy, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Clinical Poster III: Treatment

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In 2016, the American Academy of Ophthalmology (AAO) published recommendations designed to reduce hydroxychloroquine induced retinopathy via early detection and reduction of hydroxychloroquine dosing from 6.5 mg/kg to less than 5 mg/kg. We prospectively determined the frequency and the predictive role of blood levels of hydroxychloroquine to identify those at greater future risk of retinopathy. Blood hydroxychloroquine levels are preferred over plasma levels, as they more accurately reflect exposure over the last month.

Methods: 382 SLE patients were examined by ophthalmologists with retina specialization, with a fundus examination and one or more of the newer retinal screening tests: Spectral-Domain Optical Coherence Tomography (OCT); Multifocal Electroretinogram (mfERG); Microperimetry (MP1); and Fundus Autofluorescence (FAF). Hydroxychloroquine blood levels were tested at every visit and quantified by liquid chromatography-tandem mass spectrometry.

Results: Twenty-three patients had confirmed hydroxychloroquine toxicity for an overall retinopathy frequency of 4.3%. The frequency of retinopathy was: 1% in the first 5 years, 1.8% from 6 to 10 years, 3.3% from 11 to 15 years, 11.5% from 16 to 20 years, and 8.0% after 21 years of use (Table 1). Higher hydroxychloroquine blood levels (both mean and maximum) predicted later hydroxychloroquine retinopathy (Table 2).

Conclusion: The frequency of retinopathy in our prospective study was much less than in the retrospective Kaiser Permanente study. Hydroxychloroquine blood levels in the upper tertile predicted retinopathy. Mean hydroxychloroquine levels likely better predict risk than the maximum level. Hydroxychloroquine blood levels would allow clinicians to either decrease the dose or increase monitoring in those with blood levels in the highest tertile. Currently, however, availability of hydroxychloroquine blood levels has been limited.


ACR 2019-Early Prediction of Hydroxychloroquine Induced Retinopathy in SLE-Table1

Frequency of Hydroxychloroquine Retinopathy by Duration of Use


ACR 2019-Early Prediction of Hydroxychloroquine Induced Retinopathy in SLE-Table2

Hydroxychloroquine Toxicity in Each Hydroxychloroquine Blood Level Tertile


Disclosure: J. Li, None; D. Goldman, None; M. Petri, Eli Lilly and Company, 5, Exagen, 2, 5.

To cite this abstract in AMA style:

Li J, Goldman D, Petri M. Frequency and Early Prediction of Hydroxychloroquine Induced Retinopathy in SLE [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/frequency-and-early-prediction-of-hydroxychloroquine-induced-retinopathy-in-sle/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frequency-and-early-prediction-of-hydroxychloroquine-induced-retinopathy-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology